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Proteomic analysis at the sites 
of clinical infection with invasive 
Streptococcus pyogenes
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Invasive Streptococcus pyogenes infections are rare, with often-unexplained severity. Prompt diagnosis 
is desirable, as deaths can occur rapidly following onset and there is an increased, but preventable, risk 
to contacts. Here, proteomic analyses of clinical samples from invasive human S. pyogenes infections 
were undertaken to determine if novel diagnostic targets could be detected, and to augment our 
understanding of disease pathogenesis. Fluid samples from 17 patients with confirmed invasive  
S. pyogenes infection (empyema, septic arthritis, necrotising fasciitis) were analysed by proteomics for 
streptococcal and human proteins; 16/17 samples had detectable S. pyogenes DNA. Nineteen unique 
S. pyogenes proteins were identified in just 6/17 samples, and 15 of these were found in a single pleural 
fluid sample including streptococcal inhibitor of complement, trigger factor, and phosphoglycerate 
kinase. In contrast, 469 human proteins were detected in patient fluids, 177 (38%) of which could be 
identified as neutrophil proteins, including alpha enolase and lactotransferrin which, together, were 
found in all 17 samples. Our data suggest that streptococcal proteins are difficult to detect in infected 
fluid samples. A vast array of human proteins associated with leukocyte activity are, however, present 
in samples that deserve further evaluation as potential biomarkers of infection.
The important human pathogen Streptococcus pyogenes (group A Streptococcus, GAS) causes a spectrum of dis-
ease, from non-invasive throat infections to invasive necrotising fasciitis, pneumonia and septic shock. As most 
deaths from invasive GAS (iGAS) occur within 1–2 days of sample collection1, rapid diagnosis is required to ena-
ble prompt management and source control. Furthermore, although iGAS is rare, there is a 2000-fold increased 
risk of secondary cases of iGAS in household contacts, who may be protected if provided with timely advice2. 
Although iGAS can be diagnosed from blood cultures in around 80% of cases3, culture can take 24 h, and delays in 
diagnosis occur because samples from the site of infection may require specialist procedures including surgically- 
or radiologically-guided aspiration; patients may therefore be pre-exposed to systemic antimicrobials that will 
inhibit culture of microorganisms. Gram stains of samples can provide diagnoses, but lack sensitivity in septic 
arthritis compared with empyema4,5. There is therefore an urgent need for a sensitive rapid diagnostic test that 
can be undertaken on samples from patients with suspected iGAS after antimicrobials have started. Point-of-care 
rapid antigen tests for sore throat, that recognise the carbohydrate group antigen of S. pyogenes, can be adapted 
for use in iGAS infection6,7 but thus far no protein-based targets have been identified.
Several proteomic analyses of S. pyogenes have been reported, including both secreted and bacterial 
cell-associated proteomes following culture in vitro, in biofilm, and interactions with human plasma proteins8–11. 
The number of proteins detectable is often large and extends beyond those considered as classical virulence fac-
tors. Indeed, many metabolic so-called moonlighting proteins dominate the GAS secretome and could represent 
potentially important targets for immunodiagnostics. Similar to other bacteria, S. pyogenes may alter its proteome 
transiently in response to environment and growth phase; the precise growth phase of S. pyogenes during clinical 
invasive infection is uncertain. Furthermore, clinical infections are caused by a range of emm (M) genotypes that 
differ in regulatory networks and therefore may result in distinctive proteomes during infection. Indeed, this is 
apparent during broth culture8. Building on this knowledge, we set out to investigate whether S. pyogenes proteins 
could be detected in iGAS clinical samples submitted for routine culture to the diagnostic laboratory of a large 
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teaching hospital, with the primary aim of identifying potentially novel diagnostic targets; and with a secondary 
aim of examining the host proteomic response to iGAS infection.
Results
Clinical samples. Seventeen samples from patients with iGAS were obtained; of these, 7 were from patients 
with necrotising fasciitis, 7 from patients with suspected septic arthritis (2 were from the same episode, separated 
by 24 h, in a single patient), and 3 from patients with empyema. All empyema cases were caused by emm1 S. pyo-
genes in children. Septic arthritis and necrotising fasciitis cases were associated with a wider range of leading emm 
types including emm1, emm4, emm28 and emm89 (Table 1).
In all cases, S. pyogenes was cultured from a sterile site. In 14/17 cases the isolate was cultured from the fluid 
sample submitted for testing. In the remainder S. pyogenes was cultured from blood and was not cultured from the 
sample. Antibiotic exposure was not known for any of the samples. Quantitative PCR was undertaken as a surro-
gate of bacterial density and confirmed the presence of S. pyogenes DNA in all samples bar one, F6, where arthritis 
associated with bacteremia was subsequently thought to have been reactive. The median S. pyogenes genome copy 
number in the infected clinical fluids was 1.16 × 106 copies/μl (range 1.64 × 104–5.37 × 108 copies/μl).
SDS-polyacrylamide gel electrophoresis. Separation of the clinical fluid sample by SDS-polyacrylamide 
gel electrophoresis showed that most of the samples had a similar profile of proteins albeit with much variation 
in intensities (Fig. 1). An intense band at just below 70 kDa, which would be consistent with albumin was present 
in all samples, except for F9 where it was difficult to discern and appeared to be reduced in F2, F4 and F10. All 
four of these samples also appeared to lack many of the higher mass proteins evident in the other fluid samples. In 
addition, F2 appeared to lack many proteins of lower mass, whereas in F9 there appeared to be an accumulation 
of very low mass proteins.
Streptococcal proteins identified. In all, 19 different S. pyogenes proteins were identified in six of the 
fluid samples (Table 2 and Supplementary Table S1). All of the proteins were represented in the emm1 S. pyo-
genes database, however only streptococcal inhibitor of complement (SIC) and the hypothetical protein M5005_
Spy0455 were unique to emm1. All other proteins were represented in most if not all other emm-type databases 
(Supplementary Table S1). Each identification appeared to be based on good quality data according to the asso-
ciated metrics (Table 2 and Supplementary Table S1), nevertheless to further support the identifications, analysis 
of cognate bacterial supernatants was performed in parallel, to determine if the fluid proteins could be found in 
these samples as well. S. pyogenes-derived peptides identified in patient fluid samples corresponded to peptides 
from proteins also identified in cognate bacterial supernatants in all bar one case (Table 2 and Supplementary 
Table S2), thus these data further support the identification of 18 of the fluid proteins. Sixteen of the 19 S. pyogenes 
proteins were detected in fluid sample F8, two in fluid F5, and just one each in fluids F2, F4, F7 and F17.
Fluid F8 was from a case of empyema caused by emm1 S. pyogenes and contained the highest copy number 
of S. pyogenes genomes among all the fluids tested. Among the 16 S. pyogenes proteins found in fluid F8 were 
several metabolic proteins and a number of virulence factors including the emm1-specific secreted virulence 
factor streptococcal inhibitor of complement (SIC)12, histidine triad protein13, as well as trigger factor14, which 
is required for maturation of the cysteine protease, exotoxin B (SpeB). SpeB was found in just one fluid, F2, from 
Fluid no. Type of fluid Infection
culture 
+/−
Isolate 
source Isolate emm type
¶GAS DNA 
(copies/µl)
F1 Tissue exudate Necrotising fasciitis + Tissue H897§ emm4 1.96E + 04
F2 Tissue exudate Necrotising fasciitis + Tissue H894§ emm28 7.10E + 05
F3* Knee aspirate Septic arthritis + Aspirate H893 emm4 1.45E + 07
F4* Knee aspirate Septic arthritis − Aspirate H892 emm4 9.73E + 04
F5 Pleural fluid Pneumonia/Empyema + Aspirate H899 emm1 1.45E + 07
F6** Knee aspirate Reactive arthritis − Blood H832 emm28 ND
F7 Pleural fluid Empyema + Aspirate H842 emm1 1.64E + 04
F8 Pleural fluid Empyema + Aspirate H843 emm1 5.37E + 08
F9 Hip aspirate Septic arthritis + Blood H885§ emm77 3.52E + 08
F10 Knee aspirate Septic arthritis + Aspirate H657 emm89 3.23E+06
F11 Tissue exudate Necrotising fasciitis + Tissue H700§ emm89 6.11E+04
F12 Tissue exudate Necrotising fasciitis + Tissue H751 emm1 2.05E+05
F13 Tissue exudate Necrotising fasciitis + Tissue H758§ emm1 1.66E+06
F14 Elbow aspirate Septic arthritis + Aspirate H618§ emm28 1.23E+06
F15 Knee aspirate Septic arthritis − Blood H621 emm89 1.71E+04
F16 Tissue exudate Necrotising fasciitis + Tissue H627 emm4 1.33E+07
F17 Tissue exudate Necrotising fasciitis + Tissue H629§ emm1 1.09E+06
Table 1. Characteristics of the human exudate samples collected for this study. ¶GAS copy number minimum 
detection level 6.79E + 02. Any value below this was not detectable (ND). *Same patient; fluids aspirated 1 day 
apart F3 is first sample (H893); F4 was second (H892). **Arthritis thought to be reactive. §Isolates where culture 
supernatants were subject to separate proteomic analysis.
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a case of necrotising fasciitis. Phosphopyruvate hydratase and glyceraldehyde-3-phosphate dehydrogenase were 
detected in both fluid samples F5 and F8. Interestingly, the hypothetical protein M5005_Spy0455, the gene for 
which is located adjacent to a toxin-antitoxin locus15, was detected in two fluid samples, F4 and F7, but was not 
identified in either of the corresponding bacterial supernatants, suggesting that expression of this protein may be 
upregulated in vivo compared with broth culture.
To confirm the proteomic identification of a subset of proteins for which antibodies were available, immunob-
lotting was performed with C-terminal antibodies (CTAbs)8 against the S. pyogenes proteins phosphoglycerate 
Figure 1. SDS-polyacrylamide gel separation of clinical fluid sample proteins. Clinical fluids F1–F17 were 
separated by electrophoresis along with a molecular weight ladder (MWL). Following staining with coomassie 
blue each lane of the gel was cut into 22 sections, as indicated by the arrows on the lefthand side, in preparation 
for proteomic analysis as described in the Methods section. For the purpose of clarity the image shown has 
been cropped to show the lanes corresponding to the clinical fluid samples. The uncropped image is shown as 
Supplementary Figure S1.
Protein name Locus tag Fluid
Protein 
probability
No. of 
peptides
Common 
peptides
30S ribosomal protein S2 M5005_Spy1780 F8 2.5E-05 3 3/3
elongation factor G M5005_Spy0232 F8 3.6E-06 2 2/2
elongation factor Ts M5005_Spy1781 F8 4.9E-04 2 1/2
elongation factor Tu M5005_Spy0508 F8 3.4E-12 9 9/10
exotoxin B/SpeB M5005_Spy1735 F2 3.6E-08 3 3/3
fructose-bisphosphate aldolase M5005_Spy1607 F8 4.9E-05 3 3/3
Gls24 family general stress protein M5005_Spy0973 F8 1.5E-09 10 2/10
glyceraldehyde-3-phosphate dehydrogenase M5005_Spy0233 F5 9.6E-14 2 2/2
glyceraldehyde-3-phosphate dehydrogenase M5005_Spy0233 F8 1.4E-13 4 4/4
histidine triad protein M5005_Spy1710 F8 1.6E-07 3 2/3
hypothetical protein M5005_Spy0269 F8 1.2E-07 2 2/2
hypothetical protein M5005_Spy0455 F4 3.1E-04 2 0/2
hypothetical protein M5005_Spy0455 F7 6.1E-04 2 0/2
inhibitor of complement protein/SIC M5005_Spy1718 F8 1.4E-09 3 3/3
manganese-binding protein M5005_Spy0368 F8 4.0E-07 2 2/2
manganese-dependent inorganic pyrophosphatase M5005_Spy0319 F8 8.1E-09 2 2/2
molecular chaperone GroEL M5005_Spy1761 F8 2.2E-12 8 8/8
N-acetylmannosamine kinase M5005_Spy0218 F17 6.0E-04 2 2/2
phosphoglycerate kinase M5005_Spy1599 F8 2.0E-07 7 7/7
phosphopyruvate hydratase M5005_Spy0556 F5 2.0E-08 4 4/4
phosphopyruvate hydratase M5005_Spy0556 F8 1.1E-11 10 10/10
trigger factor M5005_Spy1612 F8 3.7E-06 2 1/2
Table 2. S. pyogenes proteins present in human fluid samples. The identification of each protein was determined 
by SEQUEST and was based on matching mass spectra of at least 2 different peptides for each protein. All 
proteins were matched to those from an emm1 strain, although (with the exception of inhibitor of complement 
protein and hypothetical protein M5005_Spy0455), others were also matched to most, and often all, other emm 
types examined, as detailed in Supplementary Table S1. The resultant probability calculation for each protein 
is given along with the number of peptides found. The peptide identifications were compared with results 
obtained from proteomic analysis of supernatant samples and in all cases, except for hypothetical protein 
M5005_Spy0455, between 1 and 9 peptides matching both supernatant and clinical fluid sample were found, 
providing additional confidence in these identifications.
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kinase (PGK), phosphopyruvate hydratase (enolase), SIC, SpeB, glyceraldehyde-3-phosphate dehydrogenase, 
molecular chaperone GroEL, and elongation factor G. No immunoreactive bands were detected in any fluid 
sample using the antibodies against molecular chaperone GroEL or elongation factor G. The anti-PGK antibody 
recognised single bands in fluid sample F8 and the supernatant from the corresponding cultured streptococcal 
isolate (S8), and similarly the anti-enolase antibody revealed single bands in the same samples. The anti-SIC 
antibody recognised a single band corresponding to recombinant SIC and multiple bands in both fluid sample 
F8 and the supernatant S8 with a similar distribution, except that the fluid contained more of the band with the 
lowest mass. The anti-SpeB antibody recognised a single band corresponding to recombinant SpeB, and bands 
of equivalent mass in both fluid sample F2 and the corresponding supernatant S2, as well as to a band of slightly 
higher mass in the supernatant (Fig. 2). As such, the presence of PGK, enolase, SIC and SpeB in the fluid samples 
was supported by immunoblotting.
Human proteins identified. In total, 469 different human proteins were identified in the patient samples 
(Supplementary Table S3, Supplementary Table S4). Attempts to classify these proteins automatically based on 
processes available through PANTHER (http://www.pantherdb.org/) and DAVID (https://david-d.ncifcrf.gov/) 
proved unsuccessful, possibly due to the diversity of categories utilised and the lack of relevance to the samples 
being evaluated. However, an examination of proteins individually using resources such as WikiGenes (https://
www.wikigenes.org) and UniProt (http://www.uniprot.org/) suggested that the proteins included many that 
originate from plasma as well as those involved in inflammation, particularly proteins produced by neutrophils. 
Consequently, we devised a more hypothesis-based approach where we tested this observation. This was achieved 
by comparing the fluid proteins identified with proteins previously identified in normal plasma that had been 
processed in the same way as the patient fluid samples (see Methods), and also by comparison with databases 
of proteins previously identified in neutrophils16. This approach appeared to be successful as it encompassed 
the majority of the proteins found (Fig. 3). Although numerically, fewer plasma proteins were detected com-
pared with neutrophil proteins, the plasma proteins were more consistently represented in the fluid samples 
(Supplementary Table S5). Overall, there was considerable variability between the samples with regard to the 
number and categories of proteins identified (Fig. 3). Although the samples came from patients with empy-
ema, arthritis, and necrotising fasciitis, there was no evident association between proteins identified in clini-
cal samples and specific clinical disease phenotype. Notwithstanding the non-purulent appearance and serous 
nature of the clinical fluids, a large number of proteins previously identified in neutrophils16 were identified in 
the patient samples, consistent with the infective nature of the fluids. Two neutrophil proteins (lactotransferrin 
and alpha-enolase) were present in all samples (Fig. 4). The neutrophil protein, myeloperoxidase, was present in 
all fluid samples except fluid F6, which came from a patient with suspected reactive arthritis, and did not contain 
streptococcal DNA (Fig. 4, Table 1).
A number of human proteins, of both plasma and neutrophil origin, were shown to be present in a degraded 
form, potentially reflecting proteolysis in vivo. Of particular note, multiple human proteins in fluid F9, from a 
case of septic arthritis of the hip, were shown to be degraded, having migrated in SDS-polyacrylamide gel elec-
trophoresis to a position corresponding to a mass that was lower than predicted. Although evidence of proteol-
ysis could not be demonstrated, fluid F2, which contained the streptococcal cysteine protease SpeB, contained 
remarkably few plasma proteins at all in contrast to all other samples; many of those plasma proteins that were 
Figure 2. Immunoblotting of clinical fluid samples with CTAbs. The expression of PGK, enolase, SIC, and SpeB 
in fluid samples in clinical fluid samples was confirmed using antibodies against each of these antigens. Clinical 
fluid samples F2 and F8 along with corresponding cultured supernatant samples, S2 and S8, were prepared 
and analysed as described in the Methods section along with purified preparation of SIC and SpeB. The blots 
were developed with both a CTAb antiserum and corresponding pre-immune serum in each case to ensure 
that overdevelopment was avoided and to provide evidence that the observed immunoreactivity was antigen-
specific. Blots developed using different antibodies are shown as clearly separate panels surrounded by white 
space; full length images of relevant lanes are shown.
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present in fluid F2 showed evidence of proteolysis, although we cannot exclude that this resulted from the actions 
of human neutrophil derived proteases (Fig. 4, Supplementary Table S3).
S. pyogenes virulence factors are widely reported to interact with a range of host proteins and, in some cases, 
can result in specific proteolytic cleavage. Plasma proteins that were identified at the sites of infection included 
fibronectin, all isoforms of fibrinogen, and complement factor H, although notably some of these were absent in 
some samples. Collagen I and IV were present in a minority of samples.
The properties of human proteins found in the fluid samples were examined by correspondence analy-
sis, confirming the observed heterogeneity of samples with regard to disease phenotype and protein content 
(Supplementary Figure S2).
Discussion
In this small but systematic study of samples obtained from the site of S. pyogenes infection, we were able to pos-
itively identify 19 different S. pyogenes proteins in a small number of clinical samples. The majority of bacterial 
proteins were accounted for by just one clinical sample from a patient with empyema caused by emm1 S. pyogenes. 
Similar to findings reported from earlier laboratory studies, S. pyogenes metabolic proteins that are normally con-
sidered to be cytosolic were identified most frequently. However, virulence-associated proteins such as SIC, SpeB, 
and trigger factor were also identified. In contrast to bacterial proteins, a number of human proteins common 
to neutrophils were identified in the clinical samples. Proteins such as lactotransferrin and alpha-enolase were 
reproducibly identified in all the samples, while myeloperoxidase was not identified in the absence of detectable 
bacterial DNA. Importantly, some samples showed evidence of proteolysis of human proteins.
To our knowledge, proteomic analysis of samples from patients with invasive S. pyogenes infection has not 
been previously attempted. Indeed, there are very few studies that have sought to identify bacterial proteins in 
samples from sites of infection using mass spectrometry (MS); the identification of bacterial proteins from mam-
malian hosts is considered to be difficult even in experimental in vivo models17. Many investigators have how-
ever undertaken proteomic or metabolomic analysis of serum or urine to distinguish patients with different 
categories of infection with varying degrees of success18–21. MALDI-ToF analysis of the bacterial proteome has 
Figure 3. Comparative composition of human proteins in clinical fluid samples. Human proteins in each 
of the fluid samples were categorised as originating from neutrophils, plasma or neither of these sources 
(other). Categories were based on previous proteomic identifications and do not indicate that such proteins 
are limited to these sources. (a) The total number of proteins and the contribution from each of these groups 
is indicated. The order of the fluids have been arranged to highlight the variation in the number neutrophil 
proteins detected. (b–d) Pie charts showing the relative number of commonly found proteins in each category. 
Each figure represents groups of the number of proteins found to be common amongst the 17 fluids, with values 
ranging from 1 (proteins found in just one fluid sample) to 17 (proteins found in all 17 fluid samples).
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revolutionised bacteriological colony identification in the clinical laboratory22, and there has been increasing 
interest in applying this approach to analysis of clinical specimens. However the number and quantity of bacterial 
proteins in human samples in comparison with the overwhelming number of human proteins makes such an 
approach challenging. Our aim in this work was therefore to identify dominant bacterial proteins that might act 
as targets for immunodiagnostics, where it is possible to identify analytes at a much lower concentration than 
would be feasible by liquid chromatography (LC) MS alone.
Figure 4. Distributions of the most commonly found human proteins in clinical fluid samples. Each coloured 
cell represents the presence of the protein indicated in clinical fluid samples F1–F17 (ordered so that those 
fluids with the greatest number of neutrophil proteins are to the left). The nature of the infection is indicated 
as necrotising fasciitis (NF), septic arthritis (SA), or empyema (E). Proteins identified in the clinical fluid 
samples were classified as either from neutrophil, plasma, or neither of these groups. Note that classifications do 
not indicate that such proteins are limited to these sources. Some proteins appeared with a lower mass than 
expected and these are indicated (yellow). Within each group the proteins are ordered with those proteins 
represented most frequently in the fluid samples placed at the top.
www.nature.com/scientificreports/
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Surprisingly we identified a significant number of bacterial proteins, but in a limited number of samples. 
Although the sample with greatest bacterial abundance yielded several streptococcal proteins, this was not true 
for other samples that demonstrated high bacterial loads. We speculate that proteolysis may have reduced our 
ability to detect some bacterial proteins, while the timing of sampling and antibiotic exposure may have influ-
enced this in other samples, notwithstanding the likely variable regulation of virulence by the pathogen itself. 
The findings suggest that immunoproteomic diagnostics targeted against S. pyogenes proteins may not be broadly 
effective as an approach. In contrast, molecular testing of samples for streptococcal DNA appeared to provide a 
potentially useful, quantitative result, and should be subject to further evaluation. Commercial immunodiagnos-
tic tests for S. pyogenes pharyngitis rely upon detection of the streptococcal group A carbohydrate in throat swab 
samples; the samples used in this study were not tested for the presence of group A carbohydrate and thus we 
are unable to assess if such an immunodiagnostic might be a useful diagnostic for samples from invasive disease.
Although infrequent, the streptococcal proteins identified in clinical fluids offer insight into the pathogen-
esis of iGAS. Intriguingly both SpeB and trigger factor, required for post-translational activation of SpeB, were 
detected in necrotising fasciitis and empyema samples respectively, despite experimental data that demonstrate 
downregulation of SpeB in invasive infection when S. pyogenes virulence regulator covR/S mutants are under 
selective pressure23. The findings suggest that, during clinical invasive infection, homeostatic gene regulation may 
not result in such polarised effects as are seen in experimental settings, albeit that we have measured proteins that 
may accumulate in effusions at different stages of infection. It was recently reported that S. pyogenes upregulates 
around 15 key virulence proteins in vitro, in response to acid stress, including SpeB, SIC, and histidine triad 
protein, which is required for phagocytosis resistance13. It is notable then, that these same proteins were among 
the streptococcal proteins identified in clinical samples, in addition to the many metabolic proteins identified in 
vitro. Among the bacterial proteins identified were a number of hypothetical proteins of unknown function; these 
included Spy0455, the gene for which lies adjacent to a toxin-antitoxin locus15, that was only detected in clinical 
samples in two patients, yet was not detected at all during broth culture, suggesting that this protein may have a 
particular as-yet unrecognised function in vivo.
Development of bacterial diagnostics, therapeutics, and vaccines is contingent on reliable information regard-
ing bacterial gene expression during clinical infection. Taken together, the bacterial proteomic data in this study 
underline the paucity of clinically-relevant proteomic information available regarding virulent bacterial infec-
tions in humans and highlight a need for more clinical studies. Our proteomic study provides a useful and sys-
tematic list of human proteins that are present at the sites of human group A streptococcal infection that will 
inform future studies of streptococcal pathogenesis. It is however unclear whether the human proteins identified 
in this study could act as alternative diagnostic targets for streptococcal, or other bacterial, infection, as the study 
was not designed to assess this. There is an imperative to improve diagnostic testing for septic conditions, in part 
to improve antimicrobial stewardship in hospitals in a setting where increasing antimicrobial resistance poses a 
major threat to healthcare. However, the rapidly lethal nature of invasive group A streptococcal infection provides 
a compelling rationale for a bespoke diagnostic test to assist in confirmation of disease. Based on the findings 
herein, DNA-based detection methods to detect pathogens such as S. pyogenes may be more successful than 
immunodiagnostic detection of bacterial proteins. Nonetheless, the proteomic findings related to both bacterial 
and host proteins provide useful insight for streptococcal pathogenesis research. Furthermore, although the use 
of leukocyte-derived products such as lactate dehydrogenase (LDH) to discriminate between inflammatory and 
non-inflammatory fluids is well-established, the data herein suggest that additional leukocyte biomarkers such 
as lactotransferrin, alpha-enolase, and myeloperoxidase deserve evaluation as potential biomarkers of infection.
Methods
Sample collection. Fluid samples (pleural fluid, tissue fluid, or joint fluid) aspirated from patients with sus-
pected infection admitted to hospital between January 2008- February 2012 were submitted to the diagnostic lab-
oratory for microscopy and culture. iGAS was diagnosed by positive identification of S. pyogenes from a normally 
sterile site, that is, either a blood culture or body fluid sample. Upon diagnosis of iGAS, fluid samples that had 
been refrigerated at 4 °C for a maximum of 72 h were transferred from the diagnostic laboratory to the research 
laboratory and frozen at −80 °C until analysed. Samples collected after 2010 (F1–F5; F9, F11) were treated with 
protease inhibitor cocktail (Calbiochem) before freezing; all samples in the study period were used bar those with 
a volume <1 mL.
Ethical approval. The collection and analysis of biomarkers in clinical samples from patients with suspected 
infection was approved by the West London NHS Research Ethics Committee 06/Q0406/20; methods were in 
accordance with the specified approved protocol.
Bacterial isolates. S. pyogenes isolates (n = 17) cultured from each patient were saved as glycerol stocks and 
frozen at −80 °C until required. Isolates were emm genotyped as described previously (Table 1)24. For proteomic 
analysis of bacterial culture supernatants, 7 isolates representing each of four different emm genotypes were cul-
tured in 10 ml Todd Hewitt broth at 37 °C in 5% CO2. 4 ml supernatant from overnight culture was filtered (0.2 µm 
Sartorius, Germany) and proteins precipitated using 10%w/v TCA in acetone, washed with acetone, and dried for 
1 h. The precipitate was dissolved in 250 µl of rehydration buffer (62.5 µl of 4 × LDS, 25 µl 1 M DTT and 162.5 µl of 
H2O). Proteomics was conducted on bacterial supernatants parallel with clinical samples.
Quantification of S. pyogenes genomes in clinical samples by qPCR. DNA was extracted from 50 µl 
sample by 10 min heating at 95 °C followed by genomic DNA extraction (QiaAMP DNA mini kit, Qiagen). Knee 
fluid (F6) from a bacteremic patient that had failed to yield S. pyogenes and was believed to have a reactive, not sep-
tic, arthritis was used as a comparator. The S. pyogenes housekeeping gene proS was amplified using primers ProS F 
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5′TGAGTTTATTATGAAAGACGGCTATAGTTTC and ProS R 5′-AATAGCTTCGTAAGCTTGACGATAATC 
to generate a 93 bp product. Genomic copies of proS in each sample were quantified by comparison with standard 
concentrations of a plasmid containing a single copy of proS using protocols described previously25.
SDS-polyacrylamide gel electrophoresis, in-gel tryptic digestion and LC-MS. Aliquots of each 
clinical sample containing 12.5 µg protein, except for sample 2 (25 µg) and sample 17 (6.25 µg), or 10 µg bacterial 
supernatant preparation, were treated with NuPAGE LDS Sample Buffer (ThermoFisher Scientific) containing 
40 mM dithiothreitol and heated at 90 °C for 5 min. Iodoacetamide (200 mM) was added and incubated for 20 min 
prior to loading onto a 10% polyacrylamide Tris-glycine gel. Protein mass was estimated by comparison with the 
migration of the PageRuler Prestained Protein Ladder (ThermoFisher Scientific). Separated proteins were stained 
with Instant Blue (Expedeon) and an image produced using a laser scanner. Each lane in the gel was cut into 22 
rows. The proteins present in each gel slice were digested with trypsin, and the resultant peptides extracted and 
analysed by LC-MS/MS as described previously26. The identification of proteins present in each gel slice was 
determined from analysis of the LC-MS/MS data acquired using an LTQ Linear Ion Trap Thermo Finnigan mass 
spectrometer coupled to an Agilent 1200 HPLC system for reverse phase nano LC-MS/MS peptide analysis. 
Precipitated bacterial proteins and human plasma samples were processed in a similar way.
Proteomic analysis. To identify bacterial and human proteins, data were processed using SEQUEST 
utilising a combined protein database comprising sequences derived from nine S. pyogenes genomes, i.e. M1 
(MGAS5005), M3 (MGAS315), M4 (MGAS10750), M5 (Manfredo), M6(MGAS10394), M12(MGAS2096), 
M28 (MGAS6180), M49(NZ131), M89 (H293), as well as human (refseq release 77), and pig trypsin. In addi-
tion, a decoy database was produced comprising the same composition, except with all sequences reversed. 
SEQUEST results were filtered based on peptide cross correlation scores exceeding 1.5 (single-charged ions), 
2.0 (double-charged ions) and 2.5 (triple-charged ions) and identification of at least two different peptides to a 
protein with a probability score <0.01. Analysis using the decoy database indicated a false positive rate of 1.2%. 
For human protein identification, proteins were classified as neutrophil, plasma, or non-neutrophil/non-plasma 
by comparison with a published dataset of neutrophil proteins16 and an existing dataset of proteins identified in 
human plasma processed as above (Supplementary Table S5).
Immunoblotting. Samples were separated on 10% bis-tris gels (Novex) and transferred to Hybond LFP 
membranes (GE Healthcare). Membranes were blocked with 5% skimmed milk (Sigma-Aldrich) prior to the 
addition of CTAb antibody8. Bound antibodies were detected using a 1:80,000 dilution of HRP-conjugated goat 
anti-rabbit IgG (Sigma-Aldrich) and the ECL prime detection system (GE Healthcare). Where appropriate, 
TCA-precipitated bacterial supernatants, or recombinant proteins, rSIC24 and rSpeB (Toxin Technology), were 
used as positive controls.
Correspondence analysis. The occurrence of each protein in all of the fluid samples was considered with 
respect to the deduced coverage (based on the component tryptic peptides detected) and the position of that 
protein in the SDS-polyacrylamide gel (i.e. row position, which corresponds to relative protein mass). These cri-
teria were used to classify each protein in all fluid samples using the following categories: Typical (where the row 
position that contained the maximum coverage of the protein was within an error of + or − 2 rows as that found 
in the majority of fluid samples), ‘high mass’ (where the row containing the maximum coverage was higher than 
Typical), ‘low mass’ (where the row containing the maximum coverage was less than Typical), ‘irregular’ (where 
no consistent row position corresponding to maximum coverage could be calculated), ‘single’ (if the protein was 
only detected in a single fluid sample), ‘neutrophil’ (if present in a previous proteomic analysis of neutrophils16), 
and ‘plasma’ (if the protein was also detected in normal human plasma samples). This was achieved algorthim-
ically using an Excel spreadsheet. The resultant data was then tabulated and analysed using Correspondence 
Analysis (STATISTICA, Stat Soft Inc).
Data availability. Data generated or analysed during this study are included in this published article (and its 
Supplementary Information files) or are available from the corresponding author on reasonable request.
References
 1. Lamagni, T. L. et al. Predictors of death after severe Streptococcus pyogenes infection. Emerg. Infect. Dis. 15, 1304–1307 (2009).
 2. Mearkle, R. et al. Household transmission of invasive group A Streptococcus infections in England: a population-based study, 2009, 
2011 to 2013. Euro Surveill. 22, 30532, https://doi.org/10.2807/1560-7917.ES.2017.22.19.30532 (2017).
 3. Nelson, G. E. et al. Epidemiology of Invasive Group A Streptococcal Infections in the United States, 2005–2012. Clin. Infect. Dis. 63, 
478–486 (2016).
 4. Stirling, P., Tahir, M. & Atkinson, H. D. The limitations of Gram-stain microscopy of synovial fluid in concomitant septic and crystal 
arthritis. Curr. Rheumatol. Rev. 13, https://doi.org/10.2174/1573397113666170329123308 (2017).
 5. Le Monner, A. et al. Microbiological diagnosis of empyema in children: comparative evaluations by culture, polymerase chain 
reaction, and pneumococcal antigen detection in pleural fluids. Clin. Infect. Dis. 15, 1135–1140 (2006).
 6. Gazzano, V. et al. Reassessment of the role of rapid antigen detection tests in diagnosis of invasive group A Streptococcal infections. 
J. Clin. Microbiol. 54, 994–999 (2016).
 7. Zheng, X., O’Leary, A., Uhl, J. R., Patel, R. & Shulman, S. T. Rapid detection of Streptococcus pyogenes in pleural fluid samples from 
pediatric patients with empyema. J. Clin. Microbiol. 50, 2786–2787 (2012).
 8. Edwards, R. J. et al. C-terminal antibodies (CTAbs): a simple and broadly applicable approach for the rapid generation of protein-
specific antibodies with predefined specificity. Proteomics 7, 1364–1372 (2007).
 9. Freiberg, J. A. et al. Global analysis and comparison of the transcriptomes and proteomes of group A Streptococcus biofilms. 
mSystems 6(1), e00149–16 (2016).
 10. Malmström, J. et al. Streptococcus pyogenes in human plasma: adaptive mechanisms analyzed by mass spectrometry-based 
proteomics. J. Biol. Chem. 287, 1415–1425 (2012).
www.nature.com/scientificreports/
9SCIentIFIC REPoRTS |  (2018) 8:5950  | DOI:10.1038/s41598-018-24216-2
 11. Sjöholm, K., Karlsson, C., Linder, A. & Malmström, J. A comprehensive analysis of the Streptococcus pyogenes and human plasma 
protein interaction network. Mol. Biosyst. 10, 1698–1708 (2014).
 12. Akesson, P., Sjöholm, A. G. & Björck, L. Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with 
complement function. J. Biol. Chem. 271, 1081–1088 (1996).
 13. Wen, Y. T. et al. Label-free proteomic analysis of environmental acidification-influenced Streptococcus pyogenes secretome reveals 
a novel acid-induced protein histidine triad protein A (HtpA) involved in necrotizing fasciitis. J. Proteomics 109, 90–103 (2014).
 14. Lyon, W. R., Gibson, C. M. & Caparon, M. G. A role for trigger factor and an rgg-like regulator in the transcription, secretion and 
processing of the cysteine proteinase of Streptococcus pyogenes. EMBO J. 17, 6263–6275 (1998).
 15. Sumby, P. et al. Evolutionary origin and emergence of a highly successful clone of serotype M1 group a Streptococcus involved 
multiple horizontal gene transfer events. J. Infect. Dis. 192, 771–782 (2005).
 16. Rørvig, S., Østergaard, O., Heegaard, N. H. & Borregaard, N. Proteome profiling of human neutrophil granule subsets, secretory 
vesicles, and cell membrane: correlation with transcriptome profiling of neutrophil precursors. J. Leukoc. Biol. 94, 711–721 (2013).
 17. Freiberg, J. A., McIver, K. S. & Shirtliff, M. E. In vivo expression of Streptococcus pyogenes immunogenic proteins during tibial 
foreign body infection. Infect. Immun. 82, 3891–3899 (2014).
 18. Agranoff, D. et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 368, 1012–1021 
(2006).
 19. Young, B. L. et al. The identification of tuberculosis biomarkers in human urine samples. Eur. Respir. J. 43, 1719–1729 (2014).
 20. Lau, S. K. et al. Metabolomic profiling of plasma from melioidosis patients using UHPLC-QTOF MS reveals novel biomarkers for 
diagnosis. Int. J. Mol. Sci. 17, 307, https://doi.org/10.3390/ijms17030307 (2016).
 21. Molins, C. R. et al. Development of a metabolic biosignature for detection of early Lyme disease. Clin. Infect. Dis. 60, 1767–1775 
(2015).
 22. Patel, R. MALDI-TOF MS for the diagnosis of infectious diseases. Clin. Chem. 61, 100–111 (2015).
 23. Walker, M. J. et al. DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat. Med. 13, 
981–985 (2007).
 24. Turner, C. E. et al. Molecular analysis of an outbreak of lethal postpartum sepsis caused by Streptococcus pyogenes. J. Clin. Microbiol. 
51, 2089–2095 (2013).
 25. Turner, C. E., Kurupati, P., Jones, M. D., Edwards, R. J. & Sriskandan, S. Emerging role of the IL-8 cleaving enzyme SpyCEP in 
Clinical Streptococcus pyogenes infection. J. Infect. Dis. 200, 555–563 (2009).
 26. Zhu, Z., Boobis, A. R. & Edwards, R. J. Identification of estrogen-responsive proteins in MCF-7 human breast cancer cells using 
label-free quantitative proteomics. Proteomics 8, 1987–2005 (2008).
Acknowledgements
The study was funded by the National Institute for Health Research (NIHR) Biomedical Research Centre 
awarded to Imperial College Healthcare Trust and Imperial College London, and the UKCRC (National Centre 
for Infection Prevention and Management). SS also acknowledges the support of the NIHR Health Protection 
Research Unit in Healthcare Associated Infection and Antimicrobial Resistance.
Author Contributions
R.J.E. and S.S. conceived the project and wrote the manuscript. M.P. performed the experimental work with M.G. 
contributing to the proteomic analysis and C.E.T. to the DNA analysis. V.B.A.-S. produced the human plasma 
data. All authors have read and approved the final manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-24216-2.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
